James R. Kasinger serves as Executive Vice President, General Counsel, and Corporate Secretary at CRISPR Therapeutics AG, a pioneering biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. In this role, he leads the global legal team, overseeing all aspects of corporate governance, intellectual property strategy, regulatory compliance, mergers and acquisitions, and commercial transactions. Kasinger plays a pivotal role in navigating the complex legal landscape of gene editing, ensuring the protection of CRISPR Therapeutics' groundbreaking innovations amid rapid advancements and high-stakes partnerships with industry leaders like Vertex Pharmaceuticals. Prior to joining CRISPR Therapeutics in 2017, Kasinger built a distinguished career in life sciences law. He previously served as General Counsel and Corporate Secretary at bluebird bio, where he managed legal operations during the company's growth phase, including successful public offerings and strategic collaborations. Earlier, at Ironwood Pharmaceuticals, he contributed to the commercialization of groundbreaking therapies like LINZESS, handling FDA approvals, patent prosecutions, and litigation that solidified the company's market position. His expertise spans over two decades, with early roles at Cooley LLP and other firms advising biotech startups on venture financing and IPOs. Kasinger's achievements include spearheading CRISPR Therapeutics' intellectual property portfolio, which encompasses foundational CRISPR patents, and guiding the company through landmark regulatory milestones, such as the FDA approval of CASGEVY, the first CRISPR-based therapy. A recognized leader in biotech law, he has been featured in publications like Law360 and serves on advisory boards for emerging gene therapy initiatives, underscoring his commitment to ethical innovation and patient access to cutting-edge treatments.